Pharma Focus Asia

Thermo Fisher Scientific Plans to Expand New Facility in Singapore

Introduction:

Thermo Fisher Scientific Inc, plans to invest US$130 million to expand a new facility in Singapore. The expanded sterile filling capacity will be dedicated for developing Therapies and Vaccines.

Features:

This expansion broadens the capacity for the development and manufacturing of therapies and vaccines particularly in the Asia Pacific region.

The project consists of developing two new sterile filling lines in Singapore. The first-ever high-speed sterile line approved for live virus filling and the second additional line for standard fill/finish.

The new sterile filling capacity consists of cleanroom capacity, labs and warehousing facilities to increase production. It is expected that up to 30 million sterile doses per month would be produced once the facility begins.

It is expected that the new Sterile Filling Capacity is supposed to start its operation in 2022 and add additional jobs for 300 people.

Specifications:

NameThermo Fisher Scientific
TypeExpansion
BudgetUS$130 million
Year2022
magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024